SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies

  • By

  • Pragna Patel

  • Jessica K. Sprinkles

  • Andrew Godoshian

  • Marcus Siddall

  • Timothy M. Uyeki

  • Henry Walke

  • Joseph Miller

  • November 18, 2026

Share

Objective:

To estimate the prevalence, associated factors, and antiviral treatment of SARS-CoV-2 and influenza coinfection identified through pharmacy-based testing in the United States.

Approach:
  • Design and population: Retrospective cohort of 817,834 people receiving multiplex SARS-CoV-2 and influenza A/B testing at pharmacies in 50 states, the District of Columbia, and Puerto Rico from September 1, 2023, through May 31, 2025.
  • Analysis: Researchers assessed infection prevalence, compared participant characteristics, modeled factors associated with coinfection, and used antiviral dispensing data to assess treatment.
Key Findings:
  • Coinfection prevalence was 0.081% (95% CI, 0.075%-0.087%); it was highest among children younger than 18 years at 0.145% (95% CI, 0.109%-0.186%).
  • Compared with adults aged 18 to 64 years, children had higher adjusted odds of coinfection (OR, 1.93; 95% CI, 1.42-2.57), while adults aged 65 years or older had lower odds (OR, 0.69; 95% CI, 0.53-0.89).
  • Among 665 people with coinfection, 26 (3.9%) received COVID-19 treatment and 29 (4.4%) received influenza treatment; none received treatment for both infections.
  • Among 144 symptomatic participants with coinfection who reported health histories, 92 (63.9%) reported no comorbidities.
Interpretation:

The authors reported low coinfection prevalence and low antiviral dispensing in this pharmacy-tested cohort. They identified children and people with comorbidities as groups with greater coinfection risk and noted a potential opportunity to reduce morbidity through treatment of eligible people with coinfection.

Limitations:
  • Self-reported survey data may have introduced selection bias, recall bias, and misclassification, limiting generalizability.
  • Nonresponse and prescriptions obtained elsewhere limited information on symptoms, comorbidities, severity, treatment, and outcomes.
  • The analysis did not include location-level random effects or adjust for clustering by pharmacy.
Conclusion:

The authors stated that multiplex testing in community pharmacies can identify SARS-CoV-2 and influenza coinfection and that pharmacy clinicians might consider prompt antiviral therapy for symptomatic people vulnerable to severe outcomes.

Sources:

Original Source(s)

Related Content